| Charles A Kelly, MD | |
|
40 Second Ave, Waltham, MA 02451 | |
| (617) 726-3030 | |
| Not Available |
| Full Name | Charles A Kelly |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 38 Years |
| Location | 40 Second Ave, Waltham, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083674352 | NPI | - | NPPES |
| 3060926 | Medicaid | MA | |
| J09601 | Other | MA | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 72670 (Massachusetts) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Massachusetts General Physicians Organization Inc | 2466365820 | 3085 |
News Archive
Cell Therapeutics, Inc. today announced that a comprehensive article summarizing preclinical and clinical data for pacritinib, an oral JAK2/FLT3 inhibitor, authored by Srdan Verstovsek, M.D., Ph.D., et al., was published in the journal Drugs of the Future 2013.
Tiger Woods, Kobe Bryant and A-Rod have all used it, but does platelet-rich plasma therapy (PRP) really work for the every-day active person? According to a University of Alberta Glen Sather Sports Medicine Clinic pilot study on patients with chronically sore shoulders published in PLOS ONE, preliminary findings say yes.
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
Researchers in the United States have conducted a study suggesting that the host response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within nasal mucosa is a key determinant of clinical trajectory in coronavirus disease 2019 (COVID-19).
› Verified 3 days ago
| Entity Name | Massachusetts General Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801874573 PECOS PAC ID: 2466365820 Enrollment ID: O20031111000434 |
News Archive
Cell Therapeutics, Inc. today announced that a comprehensive article summarizing preclinical and clinical data for pacritinib, an oral JAK2/FLT3 inhibitor, authored by Srdan Verstovsek, M.D., Ph.D., et al., was published in the journal Drugs of the Future 2013.
Tiger Woods, Kobe Bryant and A-Rod have all used it, but does platelet-rich plasma therapy (PRP) really work for the every-day active person? According to a University of Alberta Glen Sather Sports Medicine Clinic pilot study on patients with chronically sore shoulders published in PLOS ONE, preliminary findings say yes.
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
Researchers in the United States have conducted a study suggesting that the host response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within nasal mucosa is a key determinant of clinical trajectory in coronavirus disease 2019 (COVID-19).
› Verified 3 days ago
| Entity Name | The General Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023049236 PECOS PAC ID: 6507803806 Enrollment ID: O20080313000351 |
News Archive
Cell Therapeutics, Inc. today announced that a comprehensive article summarizing preclinical and clinical data for pacritinib, an oral JAK2/FLT3 inhibitor, authored by Srdan Verstovsek, M.D., Ph.D., et al., was published in the journal Drugs of the Future 2013.
Tiger Woods, Kobe Bryant and A-Rod have all used it, but does platelet-rich plasma therapy (PRP) really work for the every-day active person? According to a University of Alberta Glen Sather Sports Medicine Clinic pilot study on patients with chronically sore shoulders published in PLOS ONE, preliminary findings say yes.
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
Researchers in the United States have conducted a study suggesting that the host response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within nasal mucosa is a key determinant of clinical trajectory in coronavirus disease 2019 (COVID-19).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Charles A Kelly, MD Po Box 9142, Mass General Physician Organization Inc, Charlestown, MA 02129-9142 Ph: (617) 724-0287 | Charles A Kelly, MD 40 Second Ave, Waltham, MA 02451 Ph: (617) 726-3030 |
News Archive
Cell Therapeutics, Inc. today announced that a comprehensive article summarizing preclinical and clinical data for pacritinib, an oral JAK2/FLT3 inhibitor, authored by Srdan Verstovsek, M.D., Ph.D., et al., was published in the journal Drugs of the Future 2013.
Tiger Woods, Kobe Bryant and A-Rod have all used it, but does platelet-rich plasma therapy (PRP) really work for the every-day active person? According to a University of Alberta Glen Sather Sports Medicine Clinic pilot study on patients with chronically sore shoulders published in PLOS ONE, preliminary findings say yes.
TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.
Researchers in the United States have conducted a study suggesting that the host response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within nasal mucosa is a key determinant of clinical trajectory in coronavirus disease 2019 (COVID-19).
› Verified 3 days ago
Carlos F Bazoberry, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 281 Winter St Fl 2, Waltham, MA 02451 Phone: 781-895-7900 | |
David Benjamin Boyce, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 52 2nd Ave Ste 200, Waltham, MA 02451 Phone: 781-487-6971 | |
Murat A Avadikoglu, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 1440 Main St, Surgisite Boston, Waltham, MA 02451 Phone: 781-891-9300 Fax: 781-891-9305 | |
Seshagiri Rao Meka, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 20 Hope Ave, Suite 107, Waltham, MA 02453 Phone: 781-894-5522 | |
Lee Scott Silk, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 85 1st Ave, Waltham, MA 02451 Phone: 781-647-7246 | |
Juan J. Mallari, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1440 Main Street, Waltham, MA 02451 Phone: 781-891-9300 Fax: 781-891-9305 |